NC 2600

Drug Profile

NC 2600

Latest Information Update: 27 Jan 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Kyushu University; Nippon Chemiphar
  • Class Analgesics
  • Mechanism of Action Purinoceptor P2X antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Neuropathic pain

Most Recent Events

  • 26 Sep 2016 Safety and pharmacodynamic data from preclinical trials in Neuropathic pain presented at the 16th World Congress on Pain (WCP-2016)
  • 17 Jun 2016 Phase-I clinical trials in Neuropathic pain in Japan (PO)
  • 01 Jun 2015 Preclinical trials in Neuropathic pain in Japan (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top